| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 46,140 | 46,505 | 08:03 | |
| 46,140 | 46,505 | 07:48 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 52,50 | 39 | |||
| 51,00 | 30 | |||
| 46,470 | 10 | |||
| 46,370 | 346 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/brm.htm [/URL] | ||||
| 346 | 46,185 | |||
| 10 | 46,055 | |||
| 110 | 36,600 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 466 | 0,912 | 425 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:23:05 | 46,550 | 21 |
| 17:03:56 | 46,825 | 7 |
| 16:29:39 | 46,625 | 13 |
| 16:04:46 | 46,430 | 1 |
| 16:04:46 | 46,430 | 2 |
| 16:04:42 | 46,425 | 50 |
| 15:42:11 | 46,025 | 100 |
| 15:16:54 | 45,700 | 2 |
| 14:25:19 | 45,600 | 30 |
| 13:02:05 | 45,780 | 14 |
| 12:58:22 | 45,855 | 2 |
| 10:58:11 | 45,785 | 10 |
| 10:35:08 | 45,655 | 21 |
| 10:35:08 | 45,660 | 34 |
| 10:35:08 | 45,660 | 28 |
| 10:35:08 | 45,880 | 45 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln | |||||
| 01:26 | Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy | 6 | Insider Monkey | ||
| Di | Bristol-Myers Squibb Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) | 7 | Benzinga.com | ||
| So | Notable healthcare headlines for the week: J&J, Moderna, Bristol Myers in focus | 44 | Seeking Alpha | ||
| Fr | JANX Enters Global Oncology Collaboration With BMY, Stock Rises | 6 | Zacks | ||
| Do | Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic | 3 | Contract Pharma |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel to Address Gastric Bleeding Risks | ACCESS Newswire | New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.Clopidogrel, currently sold under the brand name Plavix, was... ► Artikel lesen | |
| Di | Teva Pharmaceutical Industries Ltd: Will Forte Teams Up with Teva to Get Real About Huntington's Disease with 'Honestly HD' | GlobeNewswire (Europe) | Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington's disease (HD) and chorea through Teva's Honestly HD programHD is a rare, progressive genetic disorder often... ► Artikel lesen | |
| Di | Opus Genetics, Inc.: Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa | GlobeNewswire (Europe) | The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa... ► Artikel lesen | |
| Di | Roche-Aktie: Kampf gegen Eli Lilly und Novo Nordisk | sharedeals.de | In den vergangenen zehn Jahren tat sich die Roche-Aktie nicht durch eine besonders gute Kursentwicklung hervor. Doch in den letzten drei Monaten legte der Kurs des Schweizer Pharmariesen um über +25%... ► Artikel lesen | |
| Di | Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 | ACCESS Newswire | DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen |